WHO Issues Medical Alert Over Falsified Cancer Medicine

The agency is urging healthcare providers to remain vigilant after counterfeit batches of a widely used cancer drug were identified

The World Health Organization has issued a medical product alert after counterfeit versions of the cancer medicine DARZALEX (daratumumab) were detected in the global pharmaceutical supply chain.

DARZALEX is commonly used in the treatment of multiple myeloma, a type of blood cancer. According to WHO, falsified medicines may contain incorrect ingredients or inaccurate dosages, potentially placing patients at serious risk.

The organisation has advised hospitals, pharmacies and healthcare professionals to carefully verify product packaging, batch numbers and distribution records before administering the medicine.

WHO is also encouraging national regulatory authorities to strengthen monitoring systems and report suspected counterfeit medicines promptly to reduce the risk of further circulation.

Experts warn that counterfeit medicines remain a growing global health challenge, particularly in regions with complex supply chains or limited regulatory oversight.

Patients currently receiving cancer treatment have been advised not to discontinue medication but to consult their healthcare providers if they have concerns about product authenticity.